Under the US approval,<unk>  is contraindicated for patients with severe kidney failure, end-stage renal disease, and dialysis. The European Union approval does not list any contraindications apart from hypersensitivity to the drug, which is standard for all drug approvals.
Ertugliflozin
Ipragliflozin
Linagliptin
Liraglutide
Exenatide
Vildagliptin
Saxagliptin
Sitagliptin